We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Array Technologies Inc | NASDAQ:ARRY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.12 | 0.97% | 12.46 | 12.33 | 13.26 | 13.18 | 12.285 | 12.38 | 6,324,975 | 01:00:00 |
BOULDER, Colo., Sept. 19, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
Event: |
Cantor Fitzgerald Global Healthcare Conference |
Presenter: |
Ron Squarer, Chief Executive Officer |
Date: |
Tuesday, September 26, 2017 |
Time: |
8:35 a.m. Eastern Time |
Webcast: |
http://wsw.com/webcast/cantor6/arry/ |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
CONTACT: |
Tricia Haugeto |
Array BioPharma Inc. | |
303-386-1193 | |
thaugeto@arraybiopharma.com |
View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-2017-cantor-fitzgerald-global-healthcare-conference-300520754.html
SOURCE Array BioPharma Inc.
Copyright 2017 PR Newswire
1 Year Array Technologies Chart |
1 Month Array Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions